Blistering Diseases in Newborns

Article Type
Changed
Thu, 01/10/2019 - 13:27
Display Headline
Blistering Diseases in Newborns

Review the PDF of the fact sheet on blistering diseases in newborns
with board-relevant, easy-to-review material. This fact sheet reviews the most common neonatal blistering diseases and discusses their clinical features and management.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which congenital blistering condition is caused by a mast cell growth factor receptor (KIT) mutation?

a. aplasia cutis congenita

b. bullous mastocytosis

c. congenital erosive and vesicular dermatosis

d. epidermolysis bullosa simplex

e. ichthyosis bullosa of Siemens

 

 

2. What gene mutation is present in acrodermatitis enteropathica?

a. collagen VII

b. keratin 2e

c. mast cell growth factor receptor

d. NF-κB essential modulator

e. solute carrier family 39 (zinc transporter), member 4

 

 

3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?

a. aplasia cutis congenita

b. bullous mastocytosis

c. Kindler syndrome

d. pemphigus syphiliticus

e. varicella

 

 

4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?

a. aplasia cutis congenita

b. bullous mastocytosis

c. dystrophic epidermolysis bullosa

d. Kindler syndrome

e. pemphigus syphiliticus

 

 

5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?

a. acral peeling skin syndrome

b. aplasia cutis congenita

c. bullous mastocytosis

d. dystrophic epidermolysis bullosa

e. Kindler syndrome

 

 

1. Which congenital blistering condition is caused by a mast cell growth factor (KIT) receptor mutation?

a. aplasia cutis congenita

b. bullous mastocytosis

c. congenital erosive and vesicular dermatosis

d. epidermolysis bullosa simplex

e. ichthyosis bullosa of Siemens

 

2. What gene mutation is present in acrodermatitis enteropathica?

a. collagen VII

b. keratin 2e

c. mast cell growth factor receptor

d. NF-κB essential modulator

e. solute carrier family 39 (zinc transporter), member 4

 

3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?

a. aplasia cutis congenita

b. bullous mastocytosis

c. Kindler syndrome

d. pemphigus syphiliticus

e. varicella

 

4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?

a. aplasia cutis congenita

b. bullous mastocytosis

c. dystrophic epidermolysis bullosa

d. Kindler syndrome

e. pemphigus syphiliticus

 

5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?

a. acral peeling skin syndrome

b. aplasia cutis congenita

c. bullous mastocytosis

d. dystrophic epidermolysis bullosa

e. Kindler syndrome

Article PDF
Author and Disclosure Information

Dr. Strowd is Assistant Professor of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

The author reports no conflict of interest.

Publications
Topics
Sections
Author and Disclosure Information

Dr. Strowd is Assistant Professor of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

The author reports no conflict of interest.

Author and Disclosure Information

Dr. Strowd is Assistant Professor of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles

Review the PDF of the fact sheet on blistering diseases in newborns
with board-relevant, easy-to-review material. This fact sheet reviews the most common neonatal blistering diseases and discusses their clinical features and management.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which congenital blistering condition is caused by a mast cell growth factor receptor (KIT) mutation?

a. aplasia cutis congenita

b. bullous mastocytosis

c. congenital erosive and vesicular dermatosis

d. epidermolysis bullosa simplex

e. ichthyosis bullosa of Siemens

 

 

2. What gene mutation is present in acrodermatitis enteropathica?

a. collagen VII

b. keratin 2e

c. mast cell growth factor receptor

d. NF-κB essential modulator

e. solute carrier family 39 (zinc transporter), member 4

 

 

3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?

a. aplasia cutis congenita

b. bullous mastocytosis

c. Kindler syndrome

d. pemphigus syphiliticus

e. varicella

 

 

4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?

a. aplasia cutis congenita

b. bullous mastocytosis

c. dystrophic epidermolysis bullosa

d. Kindler syndrome

e. pemphigus syphiliticus

 

 

5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?

a. acral peeling skin syndrome

b. aplasia cutis congenita

c. bullous mastocytosis

d. dystrophic epidermolysis bullosa

e. Kindler syndrome

 

 

1. Which congenital blistering condition is caused by a mast cell growth factor (KIT) receptor mutation?

a. aplasia cutis congenita

b. bullous mastocytosis

c. congenital erosive and vesicular dermatosis

d. epidermolysis bullosa simplex

e. ichthyosis bullosa of Siemens

 

2. What gene mutation is present in acrodermatitis enteropathica?

a. collagen VII

b. keratin 2e

c. mast cell growth factor receptor

d. NF-κB essential modulator

e. solute carrier family 39 (zinc transporter), member 4

 

3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?

a. aplasia cutis congenita

b. bullous mastocytosis

c. Kindler syndrome

d. pemphigus syphiliticus

e. varicella

 

4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?

a. aplasia cutis congenita

b. bullous mastocytosis

c. dystrophic epidermolysis bullosa

d. Kindler syndrome

e. pemphigus syphiliticus

 

5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?

a. acral peeling skin syndrome

b. aplasia cutis congenita

c. bullous mastocytosis

d. dystrophic epidermolysis bullosa

e. Kindler syndrome

Review the PDF of the fact sheet on blistering diseases in newborns
with board-relevant, easy-to-review material. This fact sheet reviews the most common neonatal blistering diseases and discusses their clinical features and management.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which congenital blistering condition is caused by a mast cell growth factor receptor (KIT) mutation?

a. aplasia cutis congenita

b. bullous mastocytosis

c. congenital erosive and vesicular dermatosis

d. epidermolysis bullosa simplex

e. ichthyosis bullosa of Siemens

 

 

2. What gene mutation is present in acrodermatitis enteropathica?

a. collagen VII

b. keratin 2e

c. mast cell growth factor receptor

d. NF-κB essential modulator

e. solute carrier family 39 (zinc transporter), member 4

 

 

3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?

a. aplasia cutis congenita

b. bullous mastocytosis

c. Kindler syndrome

d. pemphigus syphiliticus

e. varicella

 

 

4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?

a. aplasia cutis congenita

b. bullous mastocytosis

c. dystrophic epidermolysis bullosa

d. Kindler syndrome

e. pemphigus syphiliticus

 

 

5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?

a. acral peeling skin syndrome

b. aplasia cutis congenita

c. bullous mastocytosis

d. dystrophic epidermolysis bullosa

e. Kindler syndrome

 

 

1. Which congenital blistering condition is caused by a mast cell growth factor (KIT) receptor mutation?

a. aplasia cutis congenita

b. bullous mastocytosis

c. congenital erosive and vesicular dermatosis

d. epidermolysis bullosa simplex

e. ichthyosis bullosa of Siemens

 

2. What gene mutation is present in acrodermatitis enteropathica?

a. collagen VII

b. keratin 2e

c. mast cell growth factor receptor

d. NF-κB essential modulator

e. solute carrier family 39 (zinc transporter), member 4

 

3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?

a. aplasia cutis congenita

b. bullous mastocytosis

c. Kindler syndrome

d. pemphigus syphiliticus

e. varicella

 

4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?

a. aplasia cutis congenita

b. bullous mastocytosis

c. dystrophic epidermolysis bullosa

d. Kindler syndrome

e. pemphigus syphiliticus

 

5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?

a. acral peeling skin syndrome

b. aplasia cutis congenita

c. bullous mastocytosis

d. dystrophic epidermolysis bullosa

e. Kindler syndrome

Publications
Publications
Topics
Article Type
Display Headline
Blistering Diseases in Newborns
Display Headline
Blistering Diseases in Newborns
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Medications for Advanced Melanoma

Article Type
Changed
Thu, 01/10/2019 - 13:23
Display Headline
Medications for Advanced Melanoma

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

The answers appear on the next page.

 

 

Practice Question Answers

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

Article PDF
Author and Disclosure Information

 

Lindsay C. Strowd, MD

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Publications
Topics
Legacy Keywords
BRAF inhibitors, MEK inhibitors, antibodies, nivolumab, ipilimumab, vemurafenib, dabrafenib, alfa interferons, IL-2 cytokine, dacarbazine, aldesleukin
Sections
Author and Disclosure Information

 

Lindsay C. Strowd, MD

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Author and Disclosure Information

 

Lindsay C. Strowd, MD

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

The answers appear on the next page.

 

 

Practice Question Answers

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

 

The answers appear on the next page.

 

 

Practice Question Answers

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

3. What medication can be administered as a subcutaneous injection?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

5. Which of the following medications is an IL-2 cytokine?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib
 

Publications
Publications
Topics
Article Type
Display Headline
Medications for Advanced Melanoma
Display Headline
Medications for Advanced Melanoma
Legacy Keywords
BRAF inhibitors, MEK inhibitors, antibodies, nivolumab, ipilimumab, vemurafenib, dabrafenib, alfa interferons, IL-2 cytokine, dacarbazine, aldesleukin
Legacy Keywords
BRAF inhibitors, MEK inhibitors, antibodies, nivolumab, ipilimumab, vemurafenib, dabrafenib, alfa interferons, IL-2 cytokine, dacarbazine, aldesleukin
Sections
Disallow All Ads
Alternative CME
Article PDF Media

AIDS-Related Noninfectious Dermatoses

Article Type
Changed
Thu, 01/10/2019 - 13:20
Display Headline
AIDS-Related Noninfectious Dermatoses
Article PDF
Author and Disclosure Information

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Publications
Topics
Legacy Keywords
neoplastic, inflammatory, HIV/AIDS
Sections
Author and Disclosure Information

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Author and Disclosure Information

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles
Publications
Publications
Topics
Article Type
Display Headline
AIDS-Related Noninfectious Dermatoses
Display Headline
AIDS-Related Noninfectious Dermatoses
Legacy Keywords
neoplastic, inflammatory, HIV/AIDS
Legacy Keywords
neoplastic, inflammatory, HIV/AIDS
Sections
Disallow All Ads
Alternative CME
Article PDF Media

AIDS Infectious Dermatoses

Article Type
Changed
Thu, 01/10/2019 - 13:19
Display Headline
AIDS Infectious Dermatoses
Article PDF
Author and Disclosure Information

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Publications
Topics
Legacy Keywords
bacterial infections, fungal infections, parasitic infections, viral infections, mycobacterial infection, HIV/AIDS, candidiasis, syphilis, histoplasmosis, leishmaniasis, scabies
Sections
Author and Disclosure Information

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Author and Disclosure Information

Dr. Strowd is from Clinical Associates at Reisterstown, Maryland.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles
Publications
Publications
Topics
Article Type
Display Headline
AIDS Infectious Dermatoses
Display Headline
AIDS Infectious Dermatoses
Legacy Keywords
bacterial infections, fungal infections, parasitic infections, viral infections, mycobacterial infection, HIV/AIDS, candidiasis, syphilis, histoplasmosis, leishmaniasis, scabies
Legacy Keywords
bacterial infections, fungal infections, parasitic infections, viral infections, mycobacterial infection, HIV/AIDS, candidiasis, syphilis, histoplasmosis, leishmaniasis, scabies
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Medications in Dermatology, Part 3: Systemic Anticoagulants and Cutaneous Side Effects

Article Type
Changed
Thu, 01/10/2019 - 13:17
Display Headline
Medications in Dermatology, Part 3: Systemic Anticoagulants and Cutaneous Side Effects
Article PDF
Author and Disclosure Information

Dr. Strowd is from Clinical Associates of Reisterstown, Maryland.

The author reports no conflict of interest.

Publications
Legacy Keywords
antiplatelets, anticoagulants, thrombolytics
Sections
Author and Disclosure Information

Dr. Strowd is from Clinical Associates of Reisterstown, Maryland.

The author reports no conflict of interest.

Author and Disclosure Information

Dr. Strowd is from Clinical Associates of Reisterstown, Maryland.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles
Publications
Publications
Article Type
Display Headline
Medications in Dermatology, Part 3: Systemic Anticoagulants and Cutaneous Side Effects
Display Headline
Medications in Dermatology, Part 3: Systemic Anticoagulants and Cutaneous Side Effects
Legacy Keywords
antiplatelets, anticoagulants, thrombolytics
Legacy Keywords
antiplatelets, anticoagulants, thrombolytics
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Chemotherapeutic Agents and Dermatologic Side Effects

Article Type
Changed
Thu, 01/10/2019 - 13:13
Display Headline
Chemotherapeutic Agents and Dermatologic Side Effects
Article PDF
Author and Disclosure Information

Dr. Strowd is from Clinical Associates of Reisterstown, Maryland.

The author reports no conflict of interest.

Publications
Topics
Legacy Keywords
chemotherapy
Sections
Author and Disclosure Information

Dr. Strowd is from Clinical Associates of Reisterstown, Maryland.

The author reports no conflict of interest.

Author and Disclosure Information

Dr. Strowd is from Clinical Associates of Reisterstown, Maryland.

The author reports no conflict of interest.

Article PDF
Article PDF
Related Articles
Publications
Publications
Topics
Article Type
Display Headline
Chemotherapeutic Agents and Dermatologic Side Effects
Display Headline
Chemotherapeutic Agents and Dermatologic Side Effects
Legacy Keywords
chemotherapy
Legacy Keywords
chemotherapy
Sections
Disallow All Ads
Alternative CME
Article PDF Media